JLE

Epileptic Disorders

MENU

Developmental and epileptic encephalopathies: recognition and approaches to care Volume 23, issue 1, February 2021

  • [1] Camfield P., Camfield C. Regression in children with epilepsy. Neurosci Biobehav Rev. 2019;96:210-218.
  • [2] Scheffer I.E., Berkovic S., Capovilla G., Connolly M.B., French J., Guilhoto L. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:512-521.
  • [3] Scheffer I.E., French J., Hirsch E., Jain S., Mathern G.W., Moshé S.L. Classification of the epilepsies: New concepts for discussion and debate-Special report of the ILAE Classification Task Force of the Commission for Classification and Terminology. Open Epilepsia. 2016;1:37-44.
  • [4] Scheffer I.E., Liao J. Deciphering the concepts behind “Epileptic encephalopathy” and “Developmental and epileptic encephalopathy”. Eur J Paediatr Neurol. 2020;24:11-14.
  • [5] Kalser J., Cross J.H. The epileptic encephalopathy jungle - from Dr West to the concepts of aetiology-related and developmental encephalopathies. Curr Opin Neurol. 2018;31:216-222.
  • [6] Trivisano M., Specchio N. What are the epileptic encephalopathies? Curr Opin Neurol. 2020;33:179-184.
  • [7] Berg A.T., Berkovic S.F., Brodie M.J., Buchhalter J., Cross J.H., van Emde Boas W. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010;51:676-685.
  • [8] Happ H.C., Carvill G.L. A 2020 view on the genetics of developmental and epileptic encephalopathies. Epilepsy Curr. 2020;20:90-96.
  • [9] Na J.H., Shin S., Yang D., Kim B., Kim H.D., Kim S. Targeted gene panel sequencing in early infantile onset developmental and epileptic encephalopathy. Brain Dev. 2020;42:438-448. 6
  • [10] Hamdan F.F., Myers C.T., Cossette P., Lemay P., SpiegelmanF D., Laporte A.D. High rate of recurrent de novo mutations in developmental and epileptic encephalopathies. Am J Hum Genet. 2017;101:664-685.
  • [11] Kato M., Yamagata T., Kubota M., Arai H., Yamashita S., Nakagawa T. Clinical spectrum of early onset epileptic encephalopathies caused by KCNQ2 mutation. Epilepsia. 2013;54:1282-1287.
  • [12] Nakamura K., Kato M., Osaka H., Yamashita S., Nakagawa E., Haginoya K. Clinical spectrum of SCN2A mutations expanding to Ohtahara syndrome. Neurology. 2013;81:992-998.
  • [13] Shellhaas R.A., Wusthoff C.J., Tsuchida T.N., Glass H.C., Chu C.J., Massey S.L. Profile of neonatal epilepsies: Characteristics of a prospective US cohort. Neurology. 2017;89:893-899.
  • [14] El Kosseifi C., Cornet M.C., Cilio M.R. Neonatal developmental and epileptic encephalopathies. Semin Pediatr Neurol. 2019;32:100770.
  • [15] Caraballo R., Pavlidis E., Nikanorova M., Loddenkemper T. Encephalopathy with continuous spike-waves during slow-wave sleep: evolution and prognosis. Epileptic Disord. 2019;21:15-21.
  • [16] Shbarou R., Mikati M.A. The expanding clinical spectrum of genetic pediatric epileptic encephalopathies. Semin Pediatr Neurol. 2016;23:134-142.
  • [17] Sutter R., Kaplan P.W. Electroencephalographic criteria for nonconvulsive status epilepticus: synopsis and comprehensive survey. Epilepsia. 2012;53:1-51. 3
  • [18] Curatolo P., Nabbout R., Lagae L., Aronica E., Ferreira J.C., Feucht M. Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations. Eur J Paediatr Neurol. 2018;22:738-748.
  • [19] Gaillard W.D., Chiron C., Cross J.H., Harvey A.S, Kuzniecky R, Hertz-Pannie L. Guidelines for imaging infants and children with recent-onset epilepsy. Epilepsia. 2009;50:2147-2153.
  • [20] Tabarki B., Thabet F. Vitamin-responsive epilepsies: an update. Arch Pediatr. 2013;20:1236-1241.
  • [21] Berg A.T., Levy S.R., Testa F.M. Evolution and course of early life developmental encephalopathic epilepsies: Focus on Lennox-Gastaut syndrome. Epilepsia. 2018;59:2096-2105.
  • [22] Steward C.A., Roovers J., Suner M.M., Gonzalez J.M., Uszczynska-Ratajczak B., Pervouchine D. Re-annotation of 191 developmental and epileptic encephalopathy-associated genes unmasks de novo variants in. NPJ Genom Med. 2019;4:31.
  • [23] Korff C.M., Brunklaus A., Zuberi S.M. Epileptic activity is a surrogate for an underlying etiology and stopping the activity has a limited impact on developmental outcome. Epilepsia. 2015;56:1477-1481.
  • [24] Nabbout R., Chemaly N., Chipaux M., Barcia G., Bouis C., Dubouch C. Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy. Orphanet J Rare Dis. 2013;8:176.
  • [25] Connolly M.B. Dravet Syndrome: Diagnosis and Long-Term Course. Can J Neurol Sci. 2016;43:S3-8. 3
  • [26] De Lange I.M., Koudijs M.J., Van ’T., Slot R., Gunning B., Sonsma A.C.M, van Gemert LJJM. Mosaicism of de novo pathogenic SCN1A variants in epilepsy is a frequent phenomenon that correlates with variable phenotypes. Epilepsia. 2018;59:690-703.
  • [27] Wilmshurst J.M., Ibekwe R.C., O’callaghan F.J.K. Epileptic spasms - 175 years on: trying to teach an old dog new tricks. Seizure. 2017;44:81-86.
  • [28] O’callaghan F.J., Edwards S.W., Alber F.D., Hancock E., Johnson A.L., Kennedy C.R. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol. 2017;16:33-42.
  • [29] Riikonen R.S. Favourable prognostic factors with infantile spasms. Eur J Paediatr Neurol. 2010;14:13-18.
  • [30] Güveli B.T., Çokar Ö., Dörtcan N., Benbir G., Demirbilek V., Dervent A. Long-term outcomes in patients with West syndrome: an outpatient clinical study. Seizure. 2015;25:68-71.
  • [31] Beal J.C., Cherian K., Moshe S.L. Early-onset epileptic encephalopathies: Ohtahara syndrome and early myoclonic encephalopathy. Pediatr Neurol. 2012;47:317-323.
  • [32] Dunin-Wasowicz D., Mazurkiewicz-Beldzinska M., Steinborn B., Wheless J., Jozwiak S. Treatment of pediatric epilepsy in Poland. Eur J Paediatr Neurol. 2015;19:320-326.
  • [33] Wu J.Y., Peters J.M., Goyal M., Krueger D., Sahin M., Northrup H. Clinical electroencephalographic biomarker for impending epilepsy in asymptomatic tuberous sclerosis complex infants. Pediatr Neurol. 2016;54:29-34.
  • [34] Jansen A, Jóźwaik S, Aronica E, Kwiatkowski D. Long-term, prospective study evaluating clinical and molecular biomarkers of EPIleptogenesis in a genetic model of epilepsy–Tuberous sclerosis complex. Impact 2017: 14-16.
  • [35] O’Brien S., Ng-Cordell E., Astle D.E., Scerif G., Baker K. STXBP1-associated neurodevelopmental disorder: a comparative study of behavioural characteristics. J Neurodev Disord. 2019;11:17.
  • [36] Milh M., Boutry-Kryza N., Sutera-Sardo J., Mignot C., Auvin S., Lacoste C. Similar early characteristics but variable neurological outcome of patients with a de novo mutation of KCNQ2. Orphanet J Rare Dis. 2013;8:80.
  • [37] Brigo F., Storti M. Antiepileptic drugs for the treatment of severe myoclonic epilepsy in infancy. The Cochrane database of systematic reviews. 2013;11:CD010483.
  • [38] De Lange I.M., Gunning B., Sonsma A.C.M., van Gemert L., van Kempen M., Verbeek N.E. Influence of contraindicated medication use on cognitive outcome in Dravet syndrome and age at first afebrile seizure as a clinical predictor in SCN1A-related seizure phenotypes. Epilepsia. 2018;59:1154-1165.